Speaker Profile
PHARM.D., Pharmacogenomics Lead, Genome Medical
Biography
Gillian Bell is the Pharmacogenomics Service Lead at Genome Medical and Assistant Professor of Clinical Education in the Division of Practice Advancement and Clinical Education at UNC Eshelman School of Pharmacy. She completed her Pharm.D. at the University of Tennessee College of Pharmacy and 2 years of postgraduate training in pharmacy practice and clinical pharmacogenomics at the Memphis VAMC and St. Jude Children’s Research Hospital, respectively. Prior to joining Genome Medical, she was most recently the Director of Genetics and Personalized Medicine at Mission Health. In addition to her current role, she serves as a member of several national and international working groups focused on implementing pharmacogenomics in clinical care.
Talk
Novel Approach To A Nationwide Pharmacogenomics Medical Practice
Genome Medical is a nationwide telegenomics medical practice serving individuals, employers, providers, payers, and health systems. The PGx team consists of pharmacists, genetic counselors, medical geneticists, care coordinators, and primary care providers. Our unique telehealth services are effective and efficient in providing needed access to PGx care for various patients and entities across the country.
Session Abstract – PMWC 2022 Silicon Valley
Track Chairs:
Philip Empey, UPitt
Stuart Scott, Stanford
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.
- Keynote: The Future Of PGx
- Julie Johnson, University of Florida - Payment and Policy Landscape for PGx
- Sara Rogers, American Society of Pharmacovigilance
- PGx Research and Discovery
- Todd Skaar, Indiana University
- PGx Innovative Industry Solutions
- Jeffrey A. Shaman, Coriell Life Sciences
- Cassie Hajek, Helix
- Gillian Bell, Genome Medical
- Cindy Kosinski, 23andme
- Key Resources for PGx
- Kelly E. Caudle, St. Jude Children’s Research Hospital
- Michelle Whirl-Carillo, Stanford
- Clinical Laboratory PGx Considerations
- Ulrich Broeckel, MCW
- Stuart Scott, Stanford
- Victoria Pratt, Optum Genomics - Lessons from Frontline PGx Clinical Services
- Mark H. Dunnenberger, Northshore University HealthSystem
- Lucas Berenbrok, UPitt
- Sony Tuteja, UPenn
- Burns Blaxall, The Christ Hospital Health Network - Translational PGx Implementation Programs
- Philip Empey, UPitt
- Julie A. Johnson, Uinversity of Florida
- Laura Ramsey, Cincinnati Children's Hospital
- Nita A. Limdi, UAB
- PMWC Showcase
- Jose Estabil, Cipherome
